PCC

Daniel Carcillo is co-founder and CEO of Wesana Health (OTC: WSNAF), a data-driven life sciences company pioneering clinical therapies and drug development through the FDA pathway. A former NHL star, Carcillo won two Stanley Cups before retiring at the age of 30 due to Post-Concussion Syndrome...

Any biotech investor knows how important catalysts are for the companies in the space. One FDA approval or denial can make or break the price of the stock.  In the psychedelic space, catalysts could be even more important, as the industry as a whole is still in its infancy.  At the...

Psyched Wellness Ltd (OTCQB: PSYCF) plans to begin selling a psychoactive mushroom extract this summer that’s never been scheduled as a drug in the U.S. It’s derived from amanita muscaria, an instantly recognizable, red-capped fungi, and its active ingredient muscimol. “Everyone...

ATAI Life Sciences NV (NASDAQ: ATAI) is deploying a multipronged approach to accelerate the development of mental health treatments.  The company operates a decentralized hub and spoke model in which each of ATAI's platform companies focuses on one lead compound in a single...

If you’re just now considering the therapeutic value of psychedelics, Cybin Inc (NYSE: CYBN) is many trips ahead of you. The Toronto-based company is studying derivatives of psilocybin and DMT and plans to file an investigational new drug application with the FDA during this quarter, CEO Doug...

Larry Schnurmacher, one of Phyto Partners’ cofounders has long experience in emerging markets. His venture capital fund has greatly supported 35 cannabis companies since 2015, and, with Pytho Psyche, he began investing in psychedelics-oriented companies. More investment in this...

For many private companies, the goal is clear: to go public. For others, the goal is an acquisition. Either way, private companies offer attractive potential for investors, especially in emerging markets. And the psychedelic space is just that.  “I think we will see money leave the...

Cory Jones of Healing Maps told Benzinga’s Javier Hasse at the inaugural Benzinga Psychedelics Capital Conference on Tuesday that research underway at such institutions as Johns Hopkins University and London’s Imperial College is "changing people’s minds...

The market opportunity for legal psychedelics is in the hundreds of billions of dollars, “Shark Tank” judge Kevin O’Leary told the inaugural Benzinga Psychedelics Capital Conference on Tuesday. Investors never get the opportunity to position themselves in a brand new sector,...